Hyperlipidemia is an important risk factor for cardiovascular and cerebrovascular diseases, and its pathogenesis involves abnormal regulation of multiple key signaling pathways. Traditional Chinese medicine has the advantages of multi-target and multi-pathway in regulating lipid metabolism and improving hyperlipidemia. By intervening in signaling pathways such as adenosine monophosphate activated protein kinase, peroxisome proliferator activated receptor, sterol regulatory element binding protein, liver X receptor, and nuclear factor-κB, it can effectively regulate the synthesis and metabolism of cholesterol and triglycerides. This article reviewed the regulatory mechanisms and experimental research progress of traditional Chinese medicine compound formulas on hyperlipidemia related signaling pathways, providing theoretical basis for clinical applications and new drug development.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |